Global Autoimmune Disease Therapeutics Market is expected to reach $82.13 billion by 2022; Finds New Report

Global Autoimmune Disease Therapeutics Market is accounted for $51.2 billion in 2015 and is expected to reach $82.13 billion by 2022 growing at a CAGR of 6.9% during the forecast period. Rising healthcare expenditure in the region is one of the key factors fueling the market growth. On the other hand, insufficient funding in emerging countries and high cost involved in the treatment of the disease are hindering the market. Biologics drug acts as initial line of treatment due to therapeutic capabilities in controlling and treatment of different autoimmune complications.

North America is the largest market for autoimmune disease therapeutics due to increasing incidence of different forms of autoimmune disorders, and government initiatives in the region. Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies.

Some of the key players in the market include Johnson & Johnson Inc, Bayer Schering Pharma AG, Elan Corporation Plc, Abbott Laboratories, Genentech Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Merck & Co. Inc, Amgen Inc, Eli Lilly and Company, F. Hoffmann-La Roche AG, Biogen Idec Inc, Teva Pharmaceuticals, Industries Limited, UCB S.A., Sanofi-Aventis SA, Novartis AG and Shire Plc.

Distribution Channel:

• Drug Stores
• Hospitals
• Independent Pharmacies
• Clinics

Drug Class Covered:

• Anti-Inflammatory Drugs
• Biologics
• Immunosuppressant’s
• Nonsteroidal anti-inflammatory drugs
• Corticosteroids

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

France

Italy

UK

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

Rest of Asia Pacific

Rest of the World

Middle East

Brazil

Argentina

South Africa

Egypt

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Spanning over 137 pages “Autoimmune Disease Therapeutics - Global Market Outlook (2015-2022)” report covers Executive Summary, Preface, Market Trend Analysis, Porters Five Force Analysis, Global Autoimmune Disease Therapeutics Market, By Distribution Channel, Global Autoimmune Disease Therapeutics Market, By Drug Class, Global Autoimmune Disease Therapeutics Market, By Geography, Key Developments, Company Profiling.

For more information Visit at: http://mrr.cm/JMm

Related Reports:

Pediatric Vaccines - Global Market Outlook (2015-2022); visit at - http://mrr.cm/JMs

Companion Diagnostics - Global Market Outlook (2015-2022); visit at - http://mrr.cm/JMe

Wheelchair Medical Equipment Markets Market Share Analysis: Market Shares, Analysis, and Index, Bundle, Worldwide, 2006 to Current, Quarterly; New Report Launched

Homecare Medical Equipment Markets are poised to achieve continuing growth as the aging population needs homecare treatment. The homecare equipment market consists primarily of wheelchairs, scooters, oxygen treatment equipment, accessibility beds, lifts, and toilets. Homecare medical equipment has until recently been sold primarily through distributers. The impact of direct sales through the Internet has brought about some distribution market consolidation, leading to a decrease of in the number of distributers for homecare equipment.

As the population ages, people are more frail and need assistance for mobility. Wheelchair technology is evolving to give people with disabilities more mobility. Mobility depends on a wheelchair that is fit to purpose. Power and manual wheelchairs are bought depending on the needs of the customers. Medical scooters are a growing segment of mobility for the aging population, as they perform better in an outdoor environment. Many issues impact the choice of a wheelchair, including cost and reimbursement availability.

Spanning over 15 pages “Wheelchair Medical Equipment Markets Market Share Analysis: Market Shares, Analysis, and Index, Bundle, Worldwide, 2006 to Current, Quarterly” report covers Table of Contents 1st worksheet, Market Share 2nd worksheet, Chart Yearly 3rd worksheet, Chart Quarterly 4th worksheet, Market Analysis 5th worksheet, Market Index 6th worksheet, Company Profiles 7th worksheet, Market Forecast 8th worksheet, Chart Market Forecast 9th worksheet, Market Unit Analysis 10th worksheet, Market Unit Penetration Forecast 11th worksheet, Methods 12th worksheet, Raw Data 13th worksheet. This report Covered 15 Companies - Invacare, Pride Mobility Products Corp., Hoveround Corporation, Permobil AB, OttoBock Healthcare GmbH, Sunrise Medical, GF Health Products Inc., Merits Health Products Co. Ltd., LEVO AG, Medort Group, MEYRA, Medical Depot Inc., 21st Century Scientific, Inc., Permobil acquires ROHO, Handicare, Drive Medicals Ltd.

For more information Visit at: http://mrr.cm/JQT

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals; New Report Launched

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.

This report „T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals“ as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.

What will you find in the report?

• Profiles of 34 companies active in the field;
• Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
• Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
• Technology selection and preferences of major pharma;
• Key characteristics of technologies with clinical stage drug candidates
• Emerging alternative bi- and trispecific formats
• Target selection and competition in drug candiates
• Competition of recombinant bispecific molecules with alternative treatment modalities
• Dosing schedules of clinical stage drug candidates based on molecular features
• Economic terms of collaboration and licensing deals;

Who will benefit from the report?

• Venture capital, private equity and investment managers;
• Financial analysts;
• CFO;
• Business development and licensing (BDL) specialists;
• Marketing managers;
• CEO, COO and managing directors;
• Corporate strategy, product and portfolio analysts and managers;
• Chief Technology Officer;
• Cell technology and manufacturing specialists;
• Clinical and preclinical development specialists.

Spanning over 230 pages and 19 Tables “T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals” report covers Introduction, Executive Summary, Competitive Landscape Analysis, Company Profiles, Technology Profiles, Drug & Drug Candidate Profiles, References, Attachment. This report Covered 36 Companies - Adimab, Affimed Therapeutics, Alligator Biosciences, Ambrx, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CytomX, Eli Lilly, Emergent BioSolutions, EngMab, Eureka Therapeutics, GEMoaB, Generon, Genmab, GlaxoSmithKline, Glenmark Pharmaceuticals, ImmuneXcite, Immunocore, Immunomedics, Janssen Biotech, MacroGenics, Merus, Molecular Partners, Morphosys, Neovii Biotech, OMT Therapeutics, Pfizer, Pieris Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Servier, Wuhan YZY Biopharma, Xencor, Zymeworks.

For more information Visit at: http://mrr.cm/JQG

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Hip and Knee Orthopedic Surgical Robot Device Markets is expected to reach $5 billion by 2022; Finds New Report

The 2016 study has 156 pages, 64 tables and figures. Worldwide Orthopedic surgical robot and robotically assisted surgery markets are poised to achieve significant growth because the devices provide consistent, superior outcomes for clinicians. The accuracy provided by the robot is not reproducible by the human surgeon, so ultimately all surgeons will want to perform the orthopedic implants using this technology.

Robot assisted medial knee arthroplasty: orthopedic surgical robots are poised to take knee and hip surgery quality far beyond what has previously been available.

The quality of knee arthroplasty is improved with robotic capability. All the advantages of surgical robots carry into the Stryker Mako orthopedic reconstruction surgical products. When the knee and hip surgical robots are used, patients have less bleeding, reduction of post-operative pain, fewer re-admissions to hospital and faster recovery. Robots support high-precision surgery. A clinic in Switzerland, La Source, has reported a reduction in the average days of hospitalization from 10 to 6.

Surgical robots provide consistent reproducible precision. This capability is so significant for implant surgery that the robots are positioned to become the defacto standard of care for knee and hip surgery within five years. Any one getting a knee or hip replaced will demand clinician attention to quality of life, to maintenance of lifestyle provided by a robot when they have a joint replacement.

As next generation systems, hip and knee robotic units provide a way to improve traditional orthopedic hip and knee replacement surgery. Total hip replacement surgery has evolved dramatically as advances in technology have brought improved surgical techniques. Surgical robots and robotic assist devices are a significant part of that advance.

Once, the penetration achieves a 35% level, all orthopedic surgeons will demand that hospitals offer robotic orthopedic surgical capability because the outcomes are more predictable and better. If the hospital does not offer the robot, the surgeon will move to a more modern facility. Once some hospitals are offering superior outcomes, all hospitals must come up tot that standard, the good physicians will migrate to the good technology and the patients will follow. This market has exceeded the threshold of 100 paid successful installations, that is the watermark for strong technology growth.

Knee and hip surgical robot procedures and robotically assisted surgeries have been impacted by the reduction in insurance payments. Payment reductions have forced hospitals to start acting as businesses. The cost of delivering care has become as much a factor as providing quality care when making decisions about patient improvement in condition. Cost-cutting has been made in the supply chain. Suppliers were examined closely for quality and cost.

The number of suppliers is reduced to put pressure on the ones that remain. Those remaining are pressured to improve prices and efficiencies. Hospitals, physicians, and care providers have been financially incentivized to create accountable care organizations (ACOs). Coordinated patient care plans and value-based purchasing were rewarded. The med device buyer shifted from physicians to the ACOs and smart buying groups.

Stryker has thrived in this cost efficient environment with a surgical robot that permits faster surgeries, more cost efficient surgeries. In addition, Stryker offers an integrated system. The ability to include a Mako total knee application with Stryker Triathlon total knee system is anticipated to increase market share for Stryker. Stryker market leading Triathlon total knee system is helped in the market by the robot simply by the improved surgical technique possible. Surgical robots are proving themselves in a variety of disciplines, lending credibility to the Stryker robotic initiative.

“Use of the robot with the orthopedic implant represents a key milestone in reconstructive surgery. Robots provide an opportunity to transform orthopedics. By furthering the growth of robotic-arm assisted surgery, patients can get better treatment. By enhancing the surgeon and patient experience is is likely that the entire orthopedics implant market will grow more rapidly than it would otherwise.”

Stryker uses the Mako to perform partial knee resurfacing and is happy to add robotic capability to total knee resurfacing. Technology is enhancing a wide variety of procedures in many surgical specialties. Omni has had remarkable success with its robotic assist device. Joint stiffness and joint instability are eliminated with the use of the Omni device.

The aging US population has supported demand, since the occurrence of health issues that require medical devices is higher in the elderly population. Buoyed by strong demand and sales, industry profit margins have increased considerably during the past five years. The aging of the population worldwide is anticipated to trigger further growth of these markets.

Hospitals are adopting robotic surgical devices to improve their outcomes numbers. Hospitals are measured on outcomes, robots for surgery, when used by a trained physician are improving outcomes significantly. Hundreds of universities worldwide have research programs in robotics and many are awarding degrees in robotics. These “roboticists” are increasingly being hired by Global 2000 organizations to link mobile robots (mobile computers) into existing IT systems.

Robot-assisted surgery gives the surgeon better control over the surgical instruments and a better view of the surgical site.

Hip and knee orthopedic surgical robot device markets at $222 million in 2015 are anticipated to reach $5 billion by 2022 as next generation robotic devices, systems, and instruments are introduced to manage surgery.

The complete report provides a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success, challenges, and strategies in each segment and sub-segment. The reports cover markets for knee and hip robotic orthopedic surgery medical specialties and sub-specialties.

Spanning over 156 pages “Orthopedic Surgical Robots and Surgical Robotic Assist Robots Market Shares, Strategies, and Forecasts, Worldwide, 2016 to 2022” report covers Knee and Hip Surgical Robots Market Shares and Market Forecasts, Knee and Hip Surgical Robots Market Description and Market Dynamics, Knee and Hip Surgical Robots Market Shares and Market Forecasts, Knee and Hip Surgical Robot Products, Knee and Hip Surgical Implant Company Descriptions, Knee and Hip Surgical Company Descriptions. This report Covered 11 companies - Stryker / Mako, Omni, Smith & Nephew, Johnson & Johnson / DePuy Synthes, Shenzhen Advanced Institute, Spinal Surgical Robot, Smith & Nephew, Stryker / Mako, THINK Surgical, Wright Medical Technology, Zimmer Biomet.

For more information Visit at: http://mrr.cm/JQS

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare

Global Telecardiology Market to grow at a CAGR of 17.24% during the period 2016 - 2020; Finds New Report

Report forecast the Global Telecardiology Market to grow at a CAGR of 17.24% during the period 2016-2020.

Telecardiology is the provision of diagnosis and health monitoring of cardiac patients by physicians and healthcare professional from a distant location with the help of ICT. It is the branch of telemedicine services, which focuses on treatment of cardiovascular diseases (CVDs). Telecardiology services enable healthcare professional to access cardiac data of patient such as cardiac test results in the form of text, images and videos.

Using telecardiology, cardiology specialists can monitor patients' heart related data, ensuring quick identification of cardiac problems. During emergency, physicians can offer consultation and prescribe medicines via videoconferencing. Telecardiology technology services are also used for advanced CVDs research, training, and education.

The report covers the present scenario and the growth prospects of the Global Telecardiology Market for 2016-2020. To calculate the market size, we consider revenue generated from the following telecardiology IT solutions and services:

• IT services
• Telecom
• Software
• Hardware 

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

According to the report, a key growth driver in this market is the easy access to quality healthcare services. Telecardiology services can be accessed from a remote location through two-way doctor to patient communication system. Telecardiology services in rural areas ensure availability of high quality and advanced medical diagnosis services.

Further, the report states that one challenge that could hamper market growth is the risk associated with data privacy and security.

Global Telecardiology Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Global Telecardiology Market: BioTelemetry, Biotronik, McKesson, Philips Healthcare, and GE Healthcare.

Other Prominent Vendors in the market are: Aerotel Medical Systems, Agfa-Gevaert, Allscripts Healthcare Solutions, AMD Global Telemedicine, American Well, Cerner, Cisco Systems, CompuMed, F. Hoffmann-La Roche, Healthspot, Honeywell HomMed, Honeywell Life Care Solutions, Huawei Technologies, InTouch Technologies, LifeWatch, Meddiff Technologies, Medtronic, Polycom, Siemens Healthcare, Telemed Solutions, and Vidyo.

Market driver

• Easy access to quality healthcare services
• For a full, detailed list, view our report

Market challenge

• Data privacy and security risks
• For a full, detailed list, view our report

Market trend

• Increased adoption of cardiovascular information systems (CVIS)
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 60 pages and 21 Exhibit “Global Telecardiology Market 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Market segmentation by technology, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at: http://mrr.cm/JQ3

Related Reports;

Global Teleradiology Market 2016-2020 - Visit at - http://mrr.cm/JQU

Global Postmenopausal Osteoporosis Drugs Market 2016-2020 - Visit at - http://mrr.cm/JQw

Global Migraine Drugs Market to grow at a CAGR of 4.56% during the period 2016 - 2020; Finds New Report

Report forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.

A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.

The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

According to the report, a key market driver is the unmet needs of migraine sufferers around the world. Prophylactic therapy with improved efficacy and tolerability is one of the most significant unmet needs in individuals suffering from migraine. The US Agency for Healthcare Research and Quality estimated that only about 12% of the adults with migraines take preventive medications. The occurrence of side effects is the major reason that limits the use of migraine drugs. Moreover, there are still high levels of unmet need existing in certain niche populations, especially in patients who do not respond satisfactorily to triptans or patients for whom triptans are contraindicated.

Further, the report states that a challenge that could have a big impact on market growth is the lack of proper diagnosis of migraines.

Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Global Migraine Drugs Market: Allergan, Endo International, GlaxoSmithKline, Impax, and Pfizer.

Other Prominent Vendors in the market are: Abbott, Aegis Therapeutics, Aeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, AstraZeneca, Bayer, CoLucid, Dr. Reddy’s Laboratories, Eisai, Eli Lilly, Ethypharm, IntelGenx, Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, Pfizer, Pozen, Raptor, RedHill, SUDA, Teva, TG Therapeutics, NValeant, Winston Pharmaceuticals, and Zogenix.

Market driver

• Growing awareness about migraine and its treatment options
• For a full, detailed list, view our report

Market challenge

• Lack of proper diagnosis
• For a full, detailed list, view our report

Market trend

• Antimigraine devices and headbands
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 63 pages and 27 Exhibit “Global Migraine Drugs Market 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Disease overview, Pipeline analysis, Market segmentation by type of treatment, Market segmentation by therapeutic class, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://mrr.cm/JY2

Related Reports;

Global Ulcerative Colitis Market 2016-2020 - Visit at - http://mrr.cm/JYu

Global Resipiratory Drugs Market 2016-2020 - Visit at - http://mrr.cm/JYL

Global Endocrinology Drugs Market to grow at a CAGR of 6.69% during the period 2016 - 2020; Finds New Report

Report forecast the global endocrinology drugs market to grow at a CAGR of 6.69% during the period 2016-2020.

Endocrinology deals with the study of the endocrine system, including the biochemical and physiological functions of the hormones, cells, and tissues of the endocrine glands. Endocrine disorders can be broadly subdivided into three categories: endocrine gland hyposecretion, which causes hormone deficiency, endocrine gland hypersecretion, which causes excess hormone secretion, and tumors in the endocrine gland. The endocrine disorders considered for the present report include diabetes, human growth hormone deficiency, thyroid disorders, and male hypogonadism.

The report covers the present scenario and the growth prospects of the global endocrinology drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat and prevent type 1 and type 2 diabetes, human growth hormone deficiency, hypogonadism, and thyroid gland disorders.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

According to the report, the increase or decrease in the release of endocrine hormones leads to disorders such as diabetes, hypogonadism, hypothyroidism, and hyperthyroidism. The prevalence of diabetes is rising because of obesity, unhealthy diet, and lack of physical activity among individuals. The prevalence of hypogonadism also increases in men with diabetes, human immunodeficiency virus (HIV), chronic obstructive pulmonary disease, heart or renal disease, or in individuals who are on opiate or glucocorticoid therapy. Thus, the increase in the prevalence of these diseases will lead to the increase in the intake of medications, propelling the market growth.

Further, the report states that the patent expiry of major approved drugs is expected to impact the market adversely and slow down its growth during the forecast period.

Global Endocrinology Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Global Endocrinology Drugs Market: AbbVie Inc., AstraZeneca PLC, Eli Lilly and Co., Merck & Co, Novo Nordisk AS, and Sanofi SA.

Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Acrux DDS, Adocia, Æterna Zentaris, Akros Pharma, Allergan, Amgen, Antares Pharma, Ascendis Pharma, Astellas Pharma, Baxalta, Bayer HealthCare Pharmaceuticals, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, ChipScreen Biosciences, Clarus Therapeutics, ConjuChem, Critical Pharmaceuticals, CureDm, CymaBay Therapeutics, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Endo Pharmaceuticals, Exsulin, Ferring Pharmaceuticals, Gan & Lee Pharmaceuticals, Genentech, Generex, Genexine, Genfit, GSK, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, ILTOO Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Ipe, Islet Sciences, Janssen Pharmaceuticals, Japan Tobacco, Juniper Pharmaceuticals, Kadmon Corporation, Kamada, KinDex Pharmaceuticals, Kissei Pharmaceutical, Kotobuki, Lexicon Pharmaceuticals, LG Life Sciences, Ligand Pharmaceuticals, Lipocine, Living Cell Technologies, MacroGenics, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, MetP Pharma, Mitsubishi Tanabe Pharma, Mylan, NGM Biopharmaceuticals, Novartis, NuSirt Biopharma, OPKO Biologics, Oramed Pharmaceuticals, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, ProStrakan Group, REGiMMUNE, Repros Therapeutics, Roche, Sanwa Kagaku Kenkyusho, Sirona Biochem, Strongbridge Biopharma, Takeda Pharmaceuticals, TesoRx Pharma, Teva Pharmaceutical, Theracos, Theratechnologies, Toleranzia, Tolerion, Transition Therapeutics, VeroScience, Versartis, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, and XOMA.

Market driver

• Increase in prevalence of endocrine hormone-related diseases
• For a full, detailed list, view our report

Market challenge

• Generic erosion
• For a full, detailed list, view our report

Market trend

• Increase in outsourcing
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 118 pages and 71 Exhibit “Global Endocrinology Drugs Market 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Key buying criteria, Pipeline portfolio, Market segmentation by application, Global diabetes drugs market, Global testosterone replacement therapy market, Global human growth hormone market, Global thyroid hormone disorder drugs market, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://mrr.cm/JGV

Related Report;

Global Molecular Diagnostics Market 2016-2020 - Visit at - http://mrr.cm/JGj

Find all Healthcare reports at: http://www.marketresearchreports.com/healthcare